99mTc-Sestamibi Using a Direct Conversion Molecular Breast Imaging System to Assess Tumor Response to Neoadjuvant Chemotherapy in Women With Locally Advanced Breast Cancer
暂无分享,去创建一个
J. Boughey | D. Wahner-Roedler | D. Mitchell | M. O’Connor | C. Hruska | A. Conners | Katie N. Jones | Cindy L. Tortorelli
[1] J. Wildberger,et al. Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review , 2012, European Radiology.
[2] S. Rodenhuis,et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[3] L. Esserman,et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. , 2012, Radiology.
[4] Robert W. Maxwell,et al. Lexicon for standardized interpretation of gamma camera molecular breast imaging: observer agreement and diagnostic accuracy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[5] James A Young,et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. , 2012, The New England journal of medicine.
[6] Marc Espié,et al. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[7] M. Ross,et al. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients , 2009, Annals of surgery.
[8] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[9] J. Baselga,et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] B. Pogue,et al. Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective , 2009, Breast Cancer Research and Treatment.
[11] D. Fuster,et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[12] M. O’Connor,et al. Molecular breast imaging: use of a dual-head dedicated gamma camera to detect small breast tumors. , 2008, AJR. American journal of roentgenology.
[13] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. O’Connor,et al. Molecular breast imaging: advantages and limitations of a scintimammographic technique in patients with small breast tumors. , 2007, The breast journal.
[15] Michael K. O'Connor,et al. Molecular breast imaging using a dedicated high-performance instrument , 2006, SPIE Optics + Photonics.
[16] S. Singletary,et al. Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy , 2006, Annals of surgery.
[17] Rachel F Brem,et al. Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. , 2005, Radiology.
[18] M. O’Connor,et al. Comparison of small field of view gamma camera systems for scintimammography , 2005, Nuclear medicine communications.
[19] T. Julian,et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Wickerham,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Rainer Linke,et al. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study , 2001, European Journal of Nuclear Medicine.
[22] L. K. Harding,et al. Adsorption of radiopharmaceuticals to syringes leads to lower administered activity than intended , 2001, Nuclear medicine communications.
[23] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[24] D. Mankoff,et al. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]‐sestamibi scintimammography , 1999, Cancer.
[25] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Wickerham,et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Robert W. Maxwell,et al. Proof of concept for low-dose molecular breast imaging with a dual-head CZT gamma camera. Part II. Evaluation in patients. , 2012, Medical physics.
[28] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.